biostudies-arrayexpressLluis HernandezHomo sapienshttps://www.ebi.ac.uk/biostudies/studies/E-MTAB-16259To characterize the transcriptional impact of MALAT1 in MCL a RNAseq was performed on three SOX11-positive PDLS-MCL samples comparing MALAT1-silenced PDLS to paired controls, all cultured with pro-proliferative factors.biostudies-arrayexpressGrowth Protocol - Cells were grown with IL4, CD40L, HA-tag and BAFF as described in Araujo et al 2023 (PMID: 37031299)Nucleic Acid Extraction - Total RNA was extracted using the RNeasy Plus Micro Kit (Qiagen), quantified with Qubit, and quality-checked using Tapestation 4200 (Agilent).Sample Treatment - Silencing was performed using MALAT1 specific LNA-Gapmer (Qiagen) at 1micromolar vs Scrambled LNA-Gapmer (Qiagen) by gymnotic delivery along 5 days.Sample Collection - Peripheral blood was extracted and PBMC purified with Ficoll and cryopreserved in liquid nitrogen until the day of the experiment.Library Construction - Libraries were prepared from 10 ng of total RNA using the TAKARA_SMART-Seq® Total RNA Pico Input (ZapR® Mammalian) kit (following the manufacturer’s instructions).Sequencing - Libraries were sequenced using a NextSeq2000 (Illumina, Inc.) in paired-end mode with a read length of 2×50 bp, generating more than 60 million paired-end reads per sample.OrganizationMINSEQE ScoreAssays and DataProcessed DataMAGE-TAB FilesData Transformation - For the analysis of RNAseq data, ribosomic RNA reads were filtered out using SortMeRNA (version 4.3.4).Sequence Alignment - Kallisto (version 0.46.1). was used for high throughput sequence alignment protocolMetabolomicsUnknownTranscriptomicsGenomicsProteomicsNextSeq 2000RNA-seq of coding RNAHomo sapiensLluis HernandezfalseRNAseq of MALAT1 silencing experiments in three Patient derived lymphoma spheroids (PDLS) from Mantle Cell Lymphoma (MCL) patientsTo characterize the transcriptional impact of MALAT1 in MCL a RNAseq was performed on three SOX11-positive PDLS-MCL samples comparing MALAT1-silenced PDLS to paired controls, all cultured with pro-proliferative factors.2026-01-07T00:00:00Z2026-01-07T02:02:39.152Z2025-11-22T20:43:43.467ZE-MTAB-16259ERP185506EFO_0002944EFO_0004170EFO_0003789EFO_0004917EFO_0005518EFO_0003816EFO_0003738EFO_0004184EFO_0003969